Noubar Afeyan Overview

  • Investor Type
  • Angel

  • Investments
  • 1

  • Exits
  • 1


Noubar Afeyan General Information


Dr. Noubar Afeyan is a Co-Founder and serves as Chief Executive Officer at Flagship Pioneering. He is a Co-Founder and serves as Board Member at Montai health. He is a Co-Founder and Co-Chief Executive Officer at Harbinger Health. He is a Co-Founder and serves as Chairman at Generate Biomedicines. He is a Co-Founder and serves as Chairman at Alltrna. He co-founded and served as Chairman at Laronde. He co-founded and served as Board Member at Ohana Biosciences. He is also a Co-Founder and serves as Chairman at Omega Therapeutics. He is also a Co-Founder and serves as Board Member at Tessera. He co-founded & served as Board Member at Repertoire Immune Medicines. He co-founded Cygnal. Dr. Afeyan Co-Founded and served as Chief Executive Officer of Ensemble Therapeutics. He is a Co-Founder and Board Member of Seres Therapeutics and Cibo Technologies. He co-founded and was a Board Member of Codiak. He is an Angel Investor. He was also a Co-Founder and a Board Member at Rubius. He was also a Board Member of Sana Biotechnology. He co-founded and served as the Chairman of Evelo Biosciences. He also co-founded and served as Chairman at Ring Therapeutics. He serves as Chairman of ProFound Therapeutics. He also leads the firm's VentureLabs unit that invents and launches transformative startups. He has been a Senior Lecturer at MIT's Sloan School of Management where he has taught courses on technology entrepreneurship, innovation, and leadership since 2000. He lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation, and venture capital to biological engineering, drug discovery, medical technologies, and renewable energy. During his 28-year career as an inventor, entrepreneur, CEO, and venture capitalist, He has co-founded and helped build over 35 successful life science and technology startups. He was founder and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently, he serves on a number of public and private company boards including, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Axcella Health, and Series Therapeutics. Previously, he was a member of the founding team, director, and investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and Affinnova (acquired by AC Nielsen). He received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. He has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. He is a member of the Corporation (Board of Trustees) of MIT and a member of the Board of Overseers of the Boston Symphony Orchestra. He also serves on the boards of the Armenian General Benevolent Union, the IDeA Foundation, and the UWC Dilijan International School. Previously, he was a co-founder and board member of the National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 he received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. He was a Great Immigrant honoree of the Carnegie Corporation in 2016. He is engaged in a number of philanthropic initiatives. In 2015, he co-founded the 100 LIVES Initiative, which commemorated the 100th anniversary of the start of the Armenian genocide, and created a remembrance project to locate and preserve stories of both survivors and rescuers from the genocide. He also co-founded and served as Chairman at Axella. He has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. He co-founded and served as Board Member at Kaleido BioSciences.

Contact Information

Primary Investor Type
Angel (individual)
Primary Office
  • 55 Cambridge Parkway
  • Suite 800 East
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

Noubar Afeyan Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
0000000000 30-Apr-2015 00000 000.00 Business/Productivity Software Generating Revenue
To view Noubar Afeyan’s complete investments history, request access »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Noubar Afeyan Exits (1)

Company Name Exit Date Exit Type Exit Size
0000000000 01-Feb-2022 000000000000000000 000.00
To view Noubar Afeyan’s complete exits history, request access »

Noubar Afeyan Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Noubar Afeyan Team (1)

Name Title Deals Funds Boards Office
Noubar Afeyan Ph.D Angel Investor 00 0 00 Cambridge, MA
To view Noubar Afeyan’s complete team members history, request access »